Acuta Capital Partners LLC Purchases 1,600 Shares of Celcuity Inc. (NASDAQ:CELC)

Acuta Capital Partners LLC increased its position in Celcuity Inc. (NASDAQ:CELC) by 3.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,600 shares of the company’s stock after acquiring an additional 1,600 shares during the quarter. Acuta Capital Partners LLC owned about 0.13% of Celcuity worth $695,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Samlyn Capital LLC increased its stake in shares of Celcuity by 92.4% in the second quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock worth $21,735,000 after purchasing an additional 637,190 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Celcuity by 226.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 221,671 shares of the company’s stock valued at $3,305,000 after buying an additional 153,712 shares during the last quarter. Driehaus Capital Management LLC increased its position in Celcuity by 62.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock worth $3,351,000 after buying an additional 78,525 shares during the period. Blue Owl Capital Holdings LP acquired a new position in shares of Celcuity during the second quarter worth approximately $1,065,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Celcuity in the second quarter valued at approximately $951,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Stock Performance

NASDAQ CELC opened at $12.85 on Thursday. Celcuity Inc. has a twelve month low of $11.51 and a twelve month high of $22.19. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a market cap of $477.12 million, a P/E ratio of -4.92 and a beta of 0.76. The company’s 50-day simple moving average is $14.79 and its 200 day simple moving average is $15.79.

Analyst Ratings Changes

CELC has been the subject of several research analyst reports. Stifel Nicolaus upped their target price on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, October 7th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research report on Friday, November 15th. Lifesci Capital started coverage on Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Celcuity in a report on Friday, November 15th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $29.17.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.